Patents by Inventor Carsten Degenhart

Carsten Degenhart has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS
    Publication number: 20240415819
    Abstract: The present invention relates to certain macrocyclic compounds of the formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment or prevention of a disease associated with and/or caused by proteasome or immunoproteasome, selected from a cancer, an infectious disease, an inflammatory disease, and autoimmune disease.
    Type: Application
    Filed: September 25, 2022
    Publication date: December 19, 2024
    Inventors: Uwe Koch, Gunther Zischinsky, Anke Unger, Peter Nussbaumer, Bert Klebl, Axel Choidas, Klaus Dinkel, Julian Engel, Carsten Degenhart, Robert Huber, Kiyean Nam, Jaesung Kim, Jeongjea Seo, Seung-Joo Lee, Yeejin Jeon, Wongyun Ahn
  • INHIBITORS OF ALPHA-HEMOLYSIN OF STAPHYLOCOCCUS AUREUS
    Publication number: 20240376084
    Abstract: The present invention relates to novel inhibitors of ?-hemolysin of formula (I) and the use thereof for the prophylaxis and treatment of infections caused by Staphylococcus aureus; especially S. aureus lung infections.
    Type: Application
    Filed: July 7, 2022
    Publication date: November 14, 2024
    Inventors: Raffaella Dilucrezia, Mark Brönstrup, Ursula Bilitewski, Carsten Degenhart, Klaus Dinkel, Karoline Jerye, Eyad Kalawy Fansa, Vadim Korotkov, Eva Medina, Katharina Rox, Aditya Shekhar, Herbert Weich
  • 4-SUBSTITUTED PYRROLO[2,3-B]PYRIDINE AS ERBB MODULATORS USEFUL FOR TREATING CANCER
    Publication number: 20220370440
    Abstract: The present invention relates to certain 4-substituted 1H-pyrrolo[2,3-b]pyridine compounds of the formula (I) and pharmaceutically acceptable salts thereof. These compounds is useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of ErbB receptor, especially of Exon20 Her2 and EGFR mutations.
    Type: Application
    Filed: August 23, 2019
    Publication date: November 24, 2022
    Inventors: Carsten Schultz-Fademrecht, Bert Klebl, Peter Nussbaumer, Carsten Degenhart, Matthias Baumann